Your session is about to expire
← Back to Search
Recombinant vs Egg-Based Flu Vaccine for Adults
Study Summary
This trial will compare the clinical efficacy of a new recombinant influenza vaccine to a standard egg-based influenza vaccine among adults aged 18-64 years. The primary hypothesis is that the new vaccine is superior to the standard vaccine in preventing and attenuating influenza-like illness. Relative efficacy and immunogenicity will be assessed by comparing rates of influenza virus infection and measures of infection and illness attenuation among participants who receive the new vaccine versus the standard vaccine.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are between 18 and 64 years old.You are currently enrolled in a college or graduate degree program in the study area.You are able to read and reply to text messages or emails in English, Spanish, or Chinese without difficulty.You are currently enrolled as a student in a college or graduate degree program AND attending in-person classes with other students.You have access to the internet and a mobile phone that can send and receive text messages.You had a bad reaction to the study vaccines before.You are between 18 and 64 years old.You have a job that requires you to work in close contact with others and cannot be done from home.You currently have a job that requires you to work outside of your home and have close contact with other people for at least 20 hours per week.
- Group 1: Recombinant Influenza Vaccine (RIV)
- Group 2: Standard-Dose Inactivate Influenza Vaccine (SD IIV)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the protocol for this trial restrict participation to individuals under a certain age?
"This clinical trial permits participation from individuals aged 18 to 64. Additionally, there are 40 trials for minors and 70 for seniors."
What kind of participants are eligible for this clinical investigation?
"To qualify for inclusion in this study, participants should possess a diagnosis of influenza and be between 18 to 64 years old. Approximately 16247 individuals are being invited to participate."
Are any Canadian medical centers administering this research?
"Florida A&M University in Tallahassee, the University of Utah in Salt Lake City and Baylor College of Medicine in Houston are some of the sites that have been approved to recruit patients for this trial. Additionally, there are four other locations participating."
How many people are being enrolled in this experiment at its peak capacity?
"Affirmative. According to clinicaltrials.gov, recruitment for this research is currently underway and began on September 13th 2022. It was last updated a day later on the 14th of September, requiring 16247 volunteers from 4 different sites."
Are there vacancies available for study participants in this clinical investigation?
"According to clinicaltrials.gov, this trial is currently recruiting participants as of September 14th 2022 and was first posted on the 13th of that month."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
What site did they apply to?
Share this study with friends
Copy Link
Messenger